PRCT — PROCEPT BioRobotics Corporation stock price, charts and financials
QT33PROCEPT BioRobotics CorporationPROCEPT BioRobotics Corporation (NASDAQ: PRCT) is a Healthcare company in the Medical - Devices industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
21.71
+1.30+6.37%
News
Up 6.4% — PROCEPT BioRobotics Corporation Securities Fraud Class Action Result of Undisclosed Inventory Issues and approximately 18% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC (newsfilecorp.com).
Medium confidence
TA
Loading chart...
Snapshot
| Index | - | P/E | - | EPS (ttm) | -1.82 | Insider Own | - | Shs Outstand | 56.92M | Perf Week | 9.61% |
| Market Cap | 1.16B | Forward P/E | - | EPS next Y | -1.11 | Insider Trans | 0.79% | Shs Float | 54.61M | Perf Month | 3.34% |
| Enterprise Value | 1.01B | PEG | - | EPS next Q | - | Inst Own | - | Short Float | 14.20% | Perf Quarter | -19.77% |
| Income | -110.60M | P/S | 3.44 | EPS this Y | 8.95% | Inst Trans | - | Short Ratio | 4.94 | Perf Half Y | -25.51% |
| Sales | 337.34M | P/B | 3.39 | EPS next Y | 32.94% | ROA | -22.90% | Short Interest | 7.75M | Perf YTD | -35.12% |
| Book/sh | - | P/C | - | EPS next 5Y | - | ROE | -30.62% | 52W High | 45.43 -52.21% | Perf Year | -55.33% |
| Cash/sh | - | P/FCF | - | EPS past 3/5Y | - | ROIC | -27.35% | 52W Low | 17.73 22.44% | Perf 3Y | -43.31% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | 60.14% 107.54% | Gross Margin | 63.74% | Volatility | 9.15% 6.43% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 3.00 | EPS Y/Y TTM | -4.00% | Oper. Margin | -33.86% | ATR (14) | 1.37 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 5.35 | Sales Y/Y TTM | 43.30% | Profit Margin | -32.54% | RSI (14) | 55.08 | Recom | 2.50 |
| Dividend Gr. 3/5Y | - | Current Ratio | 6.55 | EPS Q/Q | -24.44% | SMA20 | 9.00% | Beta | 0.85 | Target Price | 22.13 |
| Payout | 0.00% | Debt/Eq | 0.23 | Sales Q/Q | 20.29% | SMA50 | -6.40% | Rel Volume | 1.02 | Prev Close | 20.41 |
| Employees | 888 | LT Debt/Eq | 0.14 | Earnings | Nov 03 | SMA200 | -24.90% | Avg Volume | 1.73M | Price | 21.71 |
| IPO Date | Sep 15, 2021 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 0.52% 3.24% | Net Debt/EBITDA | 1.49 | Volume | 1,762,017 | Change | 6.37% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Aug-05-26 | Reiterated | Truist Financial | Hold | $25 → $21 |
| Aug-05-26 | Reiterated | Robert W. Baird | $24 → $20 | |
| Aug-05-26 | Reiterated | Wells Fargo | Overweight | $34 → $19 |
| Aug-05-26 | Reiterated | Jefferies | $20 | |
| Aug-05-26 | Reiterated | Piper Sandler | Overweight | $35 → $25 |
| Aug-05-26 | Downgrade | William Blair | Outperform → Market Perform | |
| Aug-05-26 | Reiterated | Evercore ISI Group | Outperform | $30 → $23 |
| Jul-28-26 | Reiterated | UBS | $62 → $20 | |
| Jul-06-26 | Downgrade | Truist Securities | Buy → Hold | $25 |
| Jun-24-26 | Initiated | Evercore ISI | Outperform | $30 |
Latest News
Today
Today02:11PM
11:20AM
08:00AM
06:46AM
05:39AM
Aug-09-26
Aug-09-2610:55AM
Aug-07-26
Aug-07-2602:59PM
02:24PM
02:15PM
10:51AM
10:45AM
10:10AM
10:00AM
Company
PROCEPT BioRobotics Corporation specializes in pioneering surgical robotic technologies, offering innovative solutions within the field of urology. Its flagship product is the AquaBeam Robotic System, a sophisticated, image-guided surgical robot designed for minimally invasive urological procedures. This system primarily facilitates Aquablation therapy, which the company also devised, to alleviate lower urinary tract symptoms in male patients diagnosed with benign prostatic hyperplasia (BPH). As of year-end 2021, PROCEPT BioRobotics had successfully deployed 130 AquaBeam Robotic Systems across the globe, with a significant majority—78 units—located in the United States. Founded in 2007, the corporation maintains its headquarters in Redwood City, California.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 336 | 308 | 224 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 122 | 112 | 87 | — | — | — | — | — | |
| Gross Profit | 214 | 196 | 137 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 252 | 229 | 171 | — | — | — | — | — | |
| Research and Development | 77 | 71 | 62 | — | — | — | — | — | |
| Other Operating Expense | 1 | 0 | 1 | — | — | — | — | — | |
| Operating Income | -114 | -104 | -97 | — | — | — | — | — | |
| Interest Expense | 4 | 4 | 4 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 8 | 12 | 9 | — | — | — | — | — | |
| Net Income Before Taxes | -110 | -95 | -91 | — | — | — | — | — | |
| Income Taxes | 0 | 0 | 0 | — | — | — | — | — | |
| Consolidated Net Income | -110 | -96 | -91 | — | — | — | — | — | |
| Net Income From Continuing Operations | -110 | -96 | -91 | — | — | — | — | — | |
| Net Income | -110 | -96 | -91 | — | — | — | — | — | |
| EPS (Recurring) | -0.91 | -1.72 | -1.75 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -0.91 | -1.72 | -1.75 | — | — | — | — | — | |
| EPS (Diluted) | -0.91 | -1.72 | -1.75 | — | — | — | — | — | |
| EBITDA | -101 | -85 | -82 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 3.68 | 5.72 | 18.69 | — | — | — | — | — | |
| Gross Margin | 63.69 | 63.64 | 61.16 | — | — | — | — | — | |
| Operating Margin | -33.93 | -33.77 | -43.30 | — | — | — | — | — | |
| Net Margin | -32.74 | -31.17 | -40.63 | — | — | — | — | — | |
| Shares Outstanding | 57 | 56 | 52 | — | — | — | — | — | |
| Market Capitalization | 1,237 | 1,762 | 4,187 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Nouri Alaleh | EVP, CLO, CORP. SEC. | Jun 08 '26 | Sale | 28.48 | 285 | 8,117 | 105,069 | Jun 10 |
| Waters Kevin | EVP, CFO | Jun 08 '26 | Sale | 28.48 | 357 | 10,167 | 151,201 | Jun 10 |
| Templin Barry L | EVP, Chief Technology Officer | Jun 08 '26 | Sale | 28.48 | 358 | 10,195 | 68,953 | Jun 10 |
| Nouri Alaleh | EVP, CLO, CORP. SEC. | Mar 19 '26 | Sale | 25.96 | 5,363 | 139,230 | 105,354 | Mar 19 |
| Nouri Alaleh | EVP, CLO, CORP. SEC. | Mar 17 '26 | Sale | 28.15 | 304 | 8,559 | 110,717 | Mar 19 |
| Waters Kevin | EVP, CFO | Mar 17 '26 | Sale | 28.15 | 706 | 19,876 | 151,558 | Mar 19 |
| Nouri Alaleh | EVP, CLO, CORP. SEC. | Mar 10 '26 | Sale | 25.65 | 3,243 | 83,197 | 111,021 | Mar 12 |
| Desai Antal Rohit | Director | Mar 09 '26 | Buy | 24.55 | 98,699 | 2,422,890 | 426,262 | Mar 09 |
| Waters Kevin | EVP, CFO | Mar 06 '26 | Sale | 23.70 | 6,721 | 159,300 | 152,264 | Mar 09 |
| Desai Antal Rohit | Director | Mar 06 '26 | Buy | 23.59 | 160,317 | 3,781,503 | 327,563 | Mar 09 |
| Nouri Alaleh | EVP, CLO, CORP. SEC. | Mar 06 '26 | Sale | 23.70 | 6,892 | 163,353 | 114,264 | Mar 09 |
| Desai Antal Rohit | Director | Mar 05 '26 | Buy | 25.58 | 167,246 | 4,278,549 | 167,246 | Mar 09 |
| Desai Antal Rohit | Director | Aug 14 '25 | Option Exercise | 1.33 | 26,749 | 35,576 | 35,152 | Aug 15 |
| Nouri Alaleh | EVP, CLO, CORP. SEC. | Aug 14 '25 | Option Exercise | 4.52 | 11,000 | 49,720 | 72,473 | Aug 14 |
| MOLL FREDERIC H | Director | Aug 13 '25 | Buy | 39.26 | 20,000 | 785,138 | 863,159 | Aug 14 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.